Overview

Study of EXPAREL in Patients Undergoing Breast Augmentation

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 4, prospective, open-label, non-randomized, sequential study with two treatment groups differing only in the technique used for EXPAREL administration (instillation or infiltration).
Phase:
Phase 4
Details
Lead Sponsor:
Pacira Pharmaceuticals, Inc
Treatments:
Bupivacaine